Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
0.6328
-0.0289 (-4.37%)
At close: Apr 29, 2025, 4:00 PM
0.6524
+0.0196 (3.10%)
After-hours: Apr 29, 2025, 5:39 PM EDT

Company Description

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.

It developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

The company’s pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrevimab, that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19.

It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies.

The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022.

Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Invivyd, Inc.
Invivyd logo
Country United States
Founded 2020
IPO Date Aug 6, 2021
Industry Biotechnology
Sector Healthcare
Employees 100
CEO William Duke

Contact Details

Address:
1601 Trapelo Road, Suite 178
Waltham, Massachusetts 02451
United States
Phone 781 819 0080
Website invivyd.com

Stock Details

Ticker Symbol IVVD
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001832038
CUSIP Number 00534A102
ISIN Number US00534A1025
Employer ID 85-1403134
SIC Code 2836

Key Executives

Name Position
William E. Duke Jr., M.B.A. Chief Financial Officer, Principal Accounting Officer and Principal Executive Officer
Julie Green M.B.A. Chief Human Resources Officer and Head of Communications
Timothy Lee Chief Commercial Officer
Dr. Robert D. Allen Ph.D. Chief Scientific Officer
Scott Young Senior Vice President of Investor Relations and Corporate Communications
Jill Andersen J.D. Chief Legal Officer and Corporate Secretary
Dr. Mark A. Wingertzahn Ph.D. Senior Vice President of Clinical Development and Medical Affairs

Latest SEC Filings

Date Type Title
Apr 25, 2025 8-K Current Report
Apr 21, 2025 8-K Current Report
Apr 7, 2025 ARS Filing
Apr 7, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 7, 2025 DEF 14A Other definitive proxy statements
Mar 26, 2025 8-K Current Report
Mar 20, 2025 10-K Annual Report
Mar 20, 2025 8-K Current Report
Mar 5, 2025 8-K Current Report
Feb 24, 2025 8-K Current Report